Salute e Benessere

$504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch…

VANCOUVER, BC, Aug. 26, 2025 /PRNewswire/ -- USA News Group News Commentary – The healthcare AI buying spree has reached fever pitch as Microsoft, Google, and IQVIA dominate a market surging to $16.01 billion by 2030 with natural language processing tools growing at 25.3% annually. AI-enabled startups captured a stunning 62% of all digital health venture funding in the first half of 2025, pocketing $3.95 billion as institutional investors rush to capitalize on the shift from speculation to…
PR Newswire
26/08/2025

ZEISS showcases comprehensive workflow for full spectrum of retina care at…

"At ZEISS, we continue to enhance the ZEISS Retina Workflow with new capabilities, to help empower clinicians who are redefining vitreoretinal surgery and advance retinal care," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "We're excited to continue leading in this area and meeting the evolving needs of surgeons from around the world with one of the few end-to-end retina ecosystems in the industry." "At ZEISS, we…
PR Newswire
26/08/2025

HEXCLAD ANNOUNCES F1 DRIVER YUKI TSUNODA AS GLOBAL AMBASSADOR

Tsunoda, known for his fearless driving style and standout personality, is also a passionate home cook who has long dreamed of becoming a chef. Now, he's teaming up with Gordon Ramsay, one of the most iconic figures in global cuisine, for a dynamic new campaign, High Performance Cookware, with HexClad that celebrates performance at every level. In a bold creative twist, the two stars trade roles - Tsunoda steps into the kitchen, while Ramsay teases getting behind the wheel, proving that…
PR Newswire
26/08/2025

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan…

Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapyRegulatory decision supported by data from the Phase 1/2 RAINFOL™-01 trial showing encouraging responses in heavily pretreated EC patients i Rina-S continues to be...
Nasdaq GlobeNewswire
26/08/2025

5G in Healthcare Market Size worth US$ 308.24 billion by 2032 with 21.2% CAGR…

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/5g-in-healthcare-market Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/5g-in-healthcare-market Key Highlights 5G-Powered Telemedicine Set to Lead Healthcare Market with 26.1% Share by 2025 The remote care and telemedicine segment is poised to dominate the...
PR Newswire
26/08/2025

Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and…

Business Resilience Business Resilience Quality & Excellence Responsible Operations Stakeholder Centricity "At Piramal Pharma, sustainability is not just a responsibility — it is a deliberate choice that defines the way we operate and the way we grow. In today's complex environment, shaped by climate change, regulatory shifts, and rising expectations of transparency and ethical conduct, sustainability has become central to long-term value creation. This year, we have...
PR Newswire
26/08/2025

Er-Kim Announces Exclusive Agreement with CNX Therapeutics to…

Partnership will broaden portfolio distribution of oncology products to cancer patients in the specified regions Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced a distribution agreement withCNX Therapeuticsto supply selected oncology products across Central & Eastern Europe (CEE) and Türkiye.The agreement creates an exclusive partnership for a portfolio of oncology-related medications – including CNX...
Nasdaq GlobeNewswire
26/08/2025

High-Precision Base Editing Clinical Treatment for Sickle Cell Disease --…

Picture: The patient, a 21-year-old woman from Nigeria, had previously suffered from recurrent VOCs. For six months after receiving CS-101, she remains crisis-free and in good health. Picture: The patient, a 21-year-old woman fromNigeria, had previously suffered from recurrent VOCs. For six months after receiving CS-101, she remains crisis-free and in good health. Sickle Cell Disease and the Need for Curative TherapiesHemoglobinopathies — including SCD and β-thalassemia (β-thal) — are...
PR Newswire
26/08/2025

Leading US medical center chooses Sectra's enterprise imaging cloud service to…

As Sectra One Cloud is a fully managed cloud service, Sectra will monitor, optimize, and continuously upgrade the solution, alleviating the burden from the medical center's IT teams. The solution can also be scaled to accommodate growth as volumes increase and expand into other imaging specialties. As Sectra One Cloud is a fully managed cloud service, Sectra will monitor, optimize, and continuously upgrade the solution, alleviating the burden from the medical center's IT teams. The solution…
PR Newswire
26/08/2025

Publication of statement by the Board of Directors in respect of the takeover…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, August 26, 2025– With reference to Bavarian Nordic A/S' ("Bavarian Nordic" or the "Company") announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document concerning the voluntary public takeover offer to acquire all of the issued…
Nasdaq GlobeNewswire
26/08/2025

Publication of offer document in respect of the takeover offer to the…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, August 26, 2025– With reference to the announcement of 28 July 2025 (no. 21/2025) regarding the entering into of a binding agreement between Innosera ApS (the "Offeror"), a company controlled by Nordic Capital Fund XI 1and funds managed and advised by Permira...
Nasdaq GlobeNewswire
26/08/2025

Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and…

David Schilansky transitions to CEO, bringing 25 years of company-building, scaling and financing to advance Ariceum’s pipeline of novel radiotherapeuticsInitiation of Phase 1/2 SANTANA-225 study of 225Ac-SSO110 in Extensive stage small cell lung cancer (ES-SCLC) and Merkle cell carcinoma (MCC) by 2H 2025; initial data expected in 2026 BERLIN, Aug.26, 2025(GLOBE NEWSWIRE) -- Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in...
Nasdaq GlobeNewswire
26/08/2025

Curasight announces acceptance of clinical trial application (CTA) for phase 1…

Today's news means Curasight is now in clinical development with both its diagnostic (uTRACE) and therapeutic (uTREAT) platforms. Today's news means Curasight is now in clinical development with both its diagnostic (uTRACE) and therapeutic (uTREAT) platforms. "The approval of the CTA underlines the strong progress being made in developing uTREAT as a potential more targeted therapeutic solution for patients with aggressive brain cancer, where there is a strong unmet medical need,"…
PR Newswire
26/08/2025

Nicox Announces Shareholder Q&A Webpage Available

Press ReleaseNicox Announces Shareholder Q&A Webpage Available August 26, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website,www.nicox.com, including information on the most frequently asked questions for shareholders in the form of a Q&A about Nicox and its business. The Q&A...
Nasdaq GlobeNewswire
26/08/2025

BioArctic and Novartis sign an option, collaboration and license agreement using…

Under the initial research collaboration, BioArctic will generate a new drug candidate combining the BrainTransporter technology with a Novartis proprietary antibody. Should Novartis decide to exercise their option following the evaluation of the generated drug candidate, Novartis will assume full responsibility for the global development and commercialization of the drug candidate and related products. Under the initial research collaboration, BioArctic will generate a new drug candidate...
PR Newswire
26/08/2025

Angelalign Technology Announces First-Half 2025 Results While Increasing…

The growth in case shipments, along with efficient operations at treatment planning centers and clear aligner manufacturing sites, drove year-over-year improvements in revenue, gross profit, and operating profit. The Company's profitability for the Reporting Period also benefited from stringent expense management in anticipation of an uncertain tariff environment, including the delay in recruitment of certain sales and marketing, clinical support and customer service personnel, as well as delay…
PR Newswire
26/08/2025

Crohn's Disease Market Projected to Grow at 4.3% CAGR (2020-2034), Driven by…

Key Takeaways from the Crohn's Disease Market Report Key Takeaways from the Crohn's Disease Market Report Discover what is the best medicine for Crohn's disease @ Crohn's Disease Medication List Crohn's Disease Market Dynamics Crohn's disease can be managed through nutritional support, medication, and surgery in more severe cases. Treatment typically begins with glucocorticosteroids such asbudesonide, although5-Aminosalicylates (5-ASA)are considered when steroids are not...
PR Newswire
25/08/2025

Over 2,000 Successful Surgeries for Drug-Resistant Epilepsy

KFSHRC Achieves a Breakthrough in Treating Epilepsy Through Stereo-EEG Since 1993, the Epilepsy Centre has treated more than 4,000 patients and successfully performed over 2,000 epilepsy surgeries for patients unresponsive to medication, before launching the Stereo-EEG program in the last two years as a minimally invasive and advanced diagnostic tool that improves seizure localization and reduces complications.The technique represents a transformative advancement in the treatment of...
Nasdaq GlobeNewswire
25/08/2025

Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing…

The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D. The facility will create more than 1,900 jobs and support the production of next-generation metabolic medicines, including treatments for obesity These investments underscore Roche’s commitment to innovative manufacturing, designed to bring life-changing treatments to patients faster Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG;...
Nasdaq GlobeNewswire
25/08/2025

Laparoscopic Instruments Market worth $16.78 billion by 2030 with 8.7% CAGR |…

Browse in-depth TOC on "Laparoscopic Instruments Market" Browse in-depth TOC on "Laparoscopic Instruments Market" 300 - Tables 50 - Figures 330 - Pages By product,due to its wide range of procedures, including cholecystectomies, appendectomies, hernia repairs, and bowel resections- which are increasingly performed with minimally invasive techniques- general surgery dominates the market for laparoscopic instruments. Laparoscopic methods are becoming more popular because…
PR Newswire
25/08/2025

Single Cell Sequencing Market worth $3.46 billion by 2030 with 12.2% CAGR |…

Browse in-depth TOC on "Single Cell Sequencing Market" Browse in-depth TOC on "Single Cell Sequencing Market" 510 - Tables 50- Figures 500 - Pages By product type,the single cell sequencing market is segmented into consumables, instruments, and software. The consumables segment is further sub-segmented into pre-sequencing and sequencing consumables. The pre-sequencing consumables segment held the largest share of the global single-cell sequencing consumables market in 2024...
PR Newswire
25/08/2025

PCM Trials, EmVenio Research, and Clinical Trial Service Rebrand as EmVenio…

"As we combine three uniquely strong and innovative companies, we are setting a new industry standard for reach, access and precision in community-based clinical research," said Greg Austin, president of PCM Trials and now serving as president of EmVenio Clinical Research. "Joining forces solely under the EmVenio name will enable us to further succeed in making clinical research more approachable and accessible for participants to enroll and remain in studies. We're excited for…
PR Newswire
25/08/2025

Peijia Medical Announces 2025 Interim Results

Revenue from TAVR-related products increased 24.0% to RMB161.6 million, fueled by market share gains in China's transfemoral TAVR market and a favorable product mix shift toward newer premium products. Neurointerventional product revenue grew 12.2% to RMB191.8 million, supported by deeper penetration of key products and the successful launch of the YonFlow® Flow Diverting Stent. Revenue from TAVR-related products increased 24.0% toRMB161.6 million, fueled by market share gains inChina's...
PR Newswire
25/08/2025

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from…

– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines –– Substantial improvement in overall seizure burden and seizure free days observed with ongoing treatment – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug.25, 2025(GLOBE NEWSWIRE) --Biogen Inc.(Nasdaq: BIIB) andStoke Therapeutics, Inc. (Nasdaq: STOK), a...
Nasdaq GlobeNewswire
25/08/2025
Altri  Comunicati